Comparing Anheuser-Busch InBev SA/NV (NYSE:BUD) and Arcadia Biosciences (NASDAQ:RKDA)

Arcadia Biosciences (NASDAQ:RKDA) and Anheuser-Busch InBev SA/NV (NYSE:BUD) are both consumer staples companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability and institutional ownership.

Profitability

This table compares Arcadia Biosciences and Anheuser-Busch InBev SA/NV’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Arcadia Biosciences	-234.53%	-183.50%	-91.25%
Anheuser-Busch InBev SA/NV	14.90%	16.42%	7.47%

Insider and Institutional Ownership

17.7% of Arcadia Biosciences shares are owned by institutional investors. Comparatively, 5.5% of Anheuser-Busch InBev SA/NV shares are owned by institutional investors. 4.5% of Arcadia Biosciences shares are owned by company insiders. Comparatively, 4.5% of Anheuser-Busch InBev SA/NV shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Arcadia Biosciences and Anheuser-Busch InBev SA/NV, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcadia Biosciences	1	0	0	0	1.00
Anheuser-Busch InBev SA/NV	0	4	12	0	2.75

Anheuser-Busch InBev SA/NV has a consensus target price of $87.83, suggesting a potential upside of 4.33%. Given Anheuser-Busch InBev SA/NV’s stronger consensus rating and higher probable upside, analysts clearly believe Anheuser-Busch InBev SA/NV is more favorable than Arcadia Biosciences.

Valuation and Earnings

This table compares Arcadia Biosciences and Anheuser-Busch InBev SA/NV”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcadia Biosciences	$4.86 million	0.08	-$2.34 million	($4.56)	-0.04
Anheuser-Busch InBev SA/NV	$62.62 billion	2.71	$6.84 billion	$4.72	17.84

Anheuser-Busch InBev SA/NV has higher revenue and earnings than Arcadia Biosciences. Arcadia Biosciences is trading at a lower price-to-earnings ratio than Anheuser-Busch InBev SA/NV, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Arcadia Biosciences has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, Anheuser-Busch InBev SA/NV has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500.

Summary

Anheuser-Busch InBev SA/NV beats Arcadia Biosciences on 12 of the 13 factors compared between the two stocks.

About Arcadia Biosciences

Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.

About Anheuser-Busch InBev SA/NV

Anheuser-Busch InBev SA/NV produces, distributes, exports, markets, and sells beer and beverages. It offers a portfolio of approximately 500 beer brands, which primarily include Budweiser, Corona, and Stella Artois; Beck's, Hoegaarden, Leffe, and Michelob Ultra; and Aguila, Antarctica, Bud Light, Brahma, Cass, Castle, Castle Lite, Cristal, Harbin, Jupiler, Modelo Especial, Quilmes, Victoria, Sedrin, and Skol brands. The company operates in North America, Middle America, South America, Europe, the Middle East, Africa, and the Asia Pacific. The company was founded in 1366 and is headquartered in Leuven, Belgium.